The results of a first-in-human, phase I clinical trial of trastuzumab duocarmazine evaluated dose-escalation and expansion (NCT02277717) in 146 patients with HER2-positive locally progressed or metastatic solid tumors, refractory to standard cancer therapy [65]. Here, ERBB2 is linked to cancer.